Literature DB >> 16627754

High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT.

Katayoun Rezvani1, Stephan Mielke, Mojgan Ahmadzadeh, Yasemin Kilical, Bipin N Savani, Josette Zeilah, Keyvan Keyvanfar, Aldemar Montero, Nancy Hensel, Roger Kurlander, A John Barrett.   

Abstract

Regulatory T cells (T(reg)s) that constitutively express FOXP3 are instrumental to the maintenance of tolerance and may suppress graft-versus-host disease (GVHD) in humans. To determine whether regulatory T cells in allogeneic stem cell transplants (SCTs) ameliorate GVHD after transplantation, we quantitated the coexpression of FOXP3 on CD4(+) T cells in 32 donor SCTs infused into HLA-matched siblings and examined GVHD incidence in respective recipients. High CD4(+)FOXP3(+) T-cell count in the donor was associated with a reduced risk of GVHD. We monitored T(reg)s during immune reconstitution in 21 patients with leukemia undergoing a T-cell-depleted allogeneic SCT. Early after SCT, there was a significant expansion in the CD4(+)FOXP3(+) T-cell compartment. A low CD4(+)FOXP3(+) T-cell count early after SCT (day 30) was associated with an increased risk of GVHD, and the ratio of CD4(+)FOXP3(+) T cells to CD4(+)CD25(+)FOXP3(-) T cells was significantly reduced in patients with GVHD, suggesting diminished control of effector T cells. Our findings suggest that graft T(reg) content may predict for risk of GVHD after SCT. Determining the T(reg) levels in the donor and manipulating T(reg)s early after transplantation may provide a new approach to controlling GVHD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16627754      PMCID: PMC1895877          DOI: 10.1182/blood-2006-02-003996

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  Real time quantitative PCR.

Authors:  C A Heid; J Stevens; K J Livak; P M Williams
Journal:  Genome Res       Date:  1996-10       Impact factor: 9.043

2.  CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells.

Authors:  E Suri-Payer; A Z Amar; A M Thornton; E M Shevach
Journal:  J Immunol       Date:  1998-02-01       Impact factor: 5.422

Review 3.  Postthymic T-cell development.

Authors:  O Stutman
Journal:  Immunol Rev       Date:  1986-06       Impact factor: 12.988

4.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.

Authors:  S Sakaguchi; N Sakaguchi; M Asano; M Itoh; M Toda
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

5.  Quantification of cytokine mRNA expression by RT PCR in samples of previously frozen blood.

Authors:  N Kruse; M Pette; K Toyka; P Rieckmann
Journal:  J Immunol Methods       Date:  1997-12-29       Impact factor: 2.303

6.  Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  Joaquin Sanchez; Javier Casaño; Miguel A Alvarez; Jose Roman-Gomez; Carmen Martin; Francisco Martinez; Pedro Gomez; Josefina Serrano; Concepcion Herrera; Antonio Torres
Journal:  Br J Haematol       Date:  2004-09       Impact factor: 6.998

7.  T cell repopulation from functionally restricted splenic progenitors: 10,000-fold expansion documented by using limiting dilution analyses.

Authors:  R A Miller; O Stutman
Journal:  J Immunol       Date:  1984-12       Impact factor: 5.422

Review 8.  Tolerance, not immunity, crucially depends on IL-2.

Authors:  Thomas R Malek; Allison L Bayer
Journal:  Nat Rev Immunol       Date:  2004-09       Impact factor: 53.106

9.  Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells.

Authors:  Haruhiko Yagi; Takashi Nomura; Kyoko Nakamura; Sayuri Yamazaki; Toshio Kitawaki; Shohei Hori; Michiyuki Maeda; Masafumi Onodera; Takashi Uchiyama; Shingo Fujii; Shimon Sakaguchi
Journal:  Int Immunol       Date:  2004-10-04       Impact factor: 4.823

10.  In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice.

Authors:  B R Blazar; P A Taylor; P S Linsley; D A Vallera
Journal:  Blood       Date:  1994-06-15       Impact factor: 22.113

View more
  126 in total

1.  IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation.

Authors:  Anushruti Sarvaria; Rafet Basar; Rohtesh S Mehta; Hila Shaim; Muharrem Muftuoglu; Ahmad Khoder; Takuye Sekine; Elif Gokdemir; Kayo Kondo; David Marin; May Daher; Amin M Alousi; Abdullah Alsuliman; Enli Liu; Betul Oran; Amanda Olson; Roy B Jones; Uday Popat; Chitra Hosing; Richard Champlin; Elizabeth J Shpall; Katayoun Rezvani
Journal:  Blood       Date:  2016-07-20       Impact factor: 22.113

Review 2.  New and emerging therapies for acute and chronic graft versus host disease.

Authors:  LaQuisa Hill; Amin Alousi; Partow Kebriaei; Rohtesh Mehta; Katayoun Rezvani; Elizabeth Shpall
Journal:  Ther Adv Hematol       Date:  2017-11-28

Review 3.  Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective.

Authors:  F Saraceni; N Shem-Tov; A Olivieri; A Nagler
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

4.  Blood and gastric FOXP3+ T cells are not decreased in human gastric graft-versus-host disease.

Authors:  James D Lord; Robert C Hackman; Ted A Gooley; Brent L Wood; Amanda C Moklebust; David M Hockenbery; Gideon Steinbach; Steven F Ziegler; George B McDonald
Journal:  Biol Blood Marrow Transplant       Date:  2010-09-24       Impact factor: 5.742

5.  Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro.

Authors:  Xingmin Feng; Sachiko Kajigaya; Elena E Solomou; Keyvan Keyvanfar; Xiuli Xu; Nalini Raghavachari; Peter J Munson; Thomas M Herndon; Jichun Chen; Neal S Young
Journal:  Blood       Date:  2008-02-04       Impact factor: 22.113

6.  Guidelines on the use of extracorporeal photopheresis.

Authors:  R Knobler; G Berlin; P Calzavara-Pinton; H Greinix; P Jaksch; L Laroche; J Ludvigsson; P Quaglino; W Reinisch; J Scarisbrick; T Schwarz; P Wolf; P Arenberger; C Assaf; M Bagot; M Barr; A Bohbot; L Bruckner-Tuderman; B Dreno; A Enk; L French; R Gniadecki; H Gollnick; M Hertl; C Jantschitsch; A Jung; U Just; C-D Klemke; U Lippert; T Luger; E Papadavid; H Pehamberger; A Ranki; R Stadler; W Sterry; I H Wolf; M Worm; J Zic; C C Zouboulis; U Hillen
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-01       Impact factor: 6.166

7.  Tregs, HSCT, and acute GVHD: up close and personal.

Authors:  John Koreth; Jerome Ritz
Journal:  Blood       Date:  2013-09-05       Impact factor: 22.113

8.  Very Low Numbers of CD4+ FoxP3+ Tregs Expanded in Donors via TL1A-Ig and Low-Dose IL-2 Exhibit a Distinct Activation/Functional Profile and Suppress GVHD in a Preclinical Model.

Authors:  Sabrina Copsel; Dietlinde Wolf; Brandon Kale; Henry Barreras; Casey O Lightbourn; Cameron S Bader; Warren Alperstein; Norman H Altman; Krishna V Komanduri; Robert B Levy
Journal:  Biol Blood Marrow Transplant       Date:  2018-05-08       Impact factor: 5.742

9.  Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease.

Authors:  Stephan Mielke; Katayoun Rezvani; Bipin N Savani; Raquel Nunes; Agnes S M Yong; John Schindler; Roger Kurlander; Victor Ghetie; Elizabeth J Read; Scott R Solomon; Ellen S Vitetta; A John Barrett
Journal:  Blood       Date:  2007-05-03       Impact factor: 22.113

10.  Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease.

Authors:  Wei Li; Liangyi Liu; Aurelie Gomez; Jilu Zhang; Abdulraouf Ramadan; Qing Zhang; Sung W Choi; Peng Zhang; Joel K Greenson; Chen Liu; Di Jiang; Elizabeth Virts; Stephanie L Kelich; Hong Wei Chu; Ryan Flynn; Bruce R Blazar; Helmut Hanenberg; Samir Hanash; Sophie Paczesny
Journal:  JCI Insight       Date:  2016-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.